2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-160554
    C12-113 1220890-27-6 98%
    C12-113 is a lipidoid delivery agent that can be used to transfect siRNA into cells. C12-113 can also be combined with other lipids to form lipid nanoparticles (LNPs) for the delivery of mRNA encoding the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice.
    C12-113
  • HY-160675
    TCMDC-137332 165119-08-4 98%
    TCMDC-137332 is a compound that exhibits antimalarial activity against Plasmodium falciparum with an IC50 value of 7 nM. TCMDC-137332 can be utilized for the research of malaria.
    TCMDC-137332
  • HY-160832
    GC373 1429218-54-1 98%
    GC373 is a potent inhibitor of SARS-CoV-2 Mpro that blocks virus replication with an IC50 of 0.4 μM. CG373 can be utilized in anti-COVID-19 research.
    GC373
  • HY-160943
    F594-1001 1215326-44-5 98%
    F594-1001 (compound 6) is a potent and highly selective SARS-CoV-2 Mac1-ADP-ribose inhibitor with IC50s of 8.5 μM, 68 μM and 45 μM for SARS-CoV-2 in AS, FP, and FRET assays, respectively. F594-1001 directly binds to SARS-CoV-2 Mac1 and exhibits a dose-dependent inhibition of Mac1 ADP-ribosylhydrolase activity.
    F594-1001
  • HY-160995
    Crotoniazide 7007-96-7 98%
    Crotoniazide (compound 9) is an isonicotinic acid hydrazide derivative with anti-HIV potential with an EC50 value of 11 ug/mL.
    Crotoniazide
  • HY-161010
    DHFR-IN-13 98%
    DHFR-IN-13 (Compd Hit8) is an active R. solani DHFR inhibitor with an IC50 value of 10.2 μM. DHFR-IN-13 has selectivity of inhibition against human DHFR with an IC50 value of 227.7 μM. DHFR-IN-13 also is a fungicide. DHFR-IN-13 has high antifungal activity against R. solani with EC50 value of 38.2 mg/L.
    DHFR-IN-13
  • HY-161018
    CF3–K11 3032121-66-4 98%
    CF3–K11 is a stable antibiotic with antibacterial activity. CF3–K11 has strong antibacterial activity against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA).
    CF3–K11
  • HY-161047
    Antiviral agent 45 98%
    Antiviral agent 45 (compound 9a) is an antiviral agent. Antiviral agent 45 inhibits HIV-1 andHIV-2 with IC50s of 35 and 3.1 nM, respectively.
    Antiviral agent 45
  • HY-161049
    Antifungal agent 89 98%
    Antifungal agent 89 (compound 28) is a antifungal agent against Cryptococcus neoformans with minimum inhibitory concentration value ranging from 0.8 to 52.17 μM.
    Antifungal agent 89
  • HY-161065
    HKI12134085 2102393-11-1 98%
    HKI12134085 (compound 3) is an orally available antibacterial nitrobenzothiazinone (BTZ) derivative with activity against Mycobacterium tuberculosis. HKI12134085 has in vivo inhibitory potency in a BALB/c mouse model of Mycobacterium tuberculosis infection.
    HKI12134085
  • HY-161068
    hACE2/SP-IN-1 98%
    hACE2/SP-IN-1 (compound 7a) is a dual inhibitor of hACE2 and coronavirus spike protein. hACE2/SP-IN-1 can bind to the spike protein and block cell entry, preventing SARS-CoV-2 from infecting human cells.
    hACE2/SP-IN-1
  • HY-161069
    Anti-infective agent 8 98%
    Anti-infective agent 8 (compound 9d) is an antibacterial agent with an MIC of 0.5 μg/mL against Staphylococcus aureus and Mycobacterium tuberculosis H37Rv. Anti-infective agent 8 has anti-biofilm activity and significantly reduces Staphylococcus aureus biofilm formation.
    Anti-infective agent 8
  • HY-161070
    Antiviral agent 46 877660-90-7 98%
    Antiviral agent 46 (compound 4) is a derivative of cannabidiol (CBD) with anti-SARS-CoV-2 (IC50: 1.90 μM) and ACE2 activity (IC50: 1.37 μM).
    Antiviral agent 46
  • HY-161086
    Antibiofilm agent-4 3027083-73-1 98%
    Antibiofilm agent-4 (compound 4p) is a LasR inhibitor. Antibiofilm agent-4 shows the best antibiofilm and anti-QS properties.
    Antibiofilm agent-4
  • HY-161094
    Metallo-β-lactamase-IN-12 3028594-43-3 98%
    Metallo-β-lactamase-IN-12 is a dual inhibitor of metal β-lactamases (MβLs (NDM-1, IMP-1)) and serine β-lactamases (SβLs (OXA-48, KPC-2)), with IC50 values of 0.64 μM, 1.32 μM, 1.01 μM, and 0.57 μM, respectively. Metallo-β-lactamase-IN-12 has antibacterial activity.
    Metallo-β-lactamase-IN-12
  • HY-161097
    Antibacterial agent 171 98%
    Antibacterial agent 171 (Compound 28) is an antibacterial agent. Antibacterial agent 171 inhibits gram-negative bacteria.
    Antibacterial agent 171
  • HY-161114
    MDOLL-0229 3036752-42-5 98%
    MDOLL-0229 (compound 27) is an antiviral agent that targets SARS-CoV-2 Mac1 and repress coronavirus replication. MDOLL-0229 inhibits SARS-CoV-2 Mac1 with an IC50 of 2.1 µM.
    MDOLL-0229
  • HY-161124
    SrtA-IN-2 98%
    SrtA-IN-2 (compound Y40), a ML346 (HY-18669) analog, is a Sortase A (SrtA) inhibitor. SrtA-IN-2 shows inhibitory activity on Staphylococcus aureus SrtA and shows inhibitory effects on biofilm formation. SrtA-IN-2 is an antivirulence agent against S. aureus infections.
    SrtA-IN-2
  • HY-161172
    Antibacterial agent 178 98%
    Antibacterial agent 178 (compound A10) is a potent antibacterial agent. Antibacterial agent 178 shows antibacterial activities for Xanthomonas oryzae pv. oryzae and Xanthomonas oryzae pv. oryzicola with EC50s of 5.32 mg/L and 7.58 mg/L, respectively. Antibacterial agent 178 targets the translational regulator (CsrA) and the virulence regulator (Xoc3530).
    Antibacterial agent 178
  • HY-161239
    (S)-IB-96212 98%
    (S)-IB-96212 (compound 4), an oligomycin derivative, inhibits the MurD2 reaction, but not the MurL reaction. (S)-IB-96212 is a specific inhibitor of the alternative pathway of peptidoglycan biosynthesis. (S)-IB-96212 weakly inhibits the MurD reaction.
    (S)-IB-96212
Cat. No. Product Name / Synonyms Application Reactivity